273 related articles for article (PubMed ID: 29734514)
1. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.
Nishida N; Kudo M
Hepatol Res; 2018 Jul; 48(8):622-634. PubMed ID: 29734514
[TBL] [Abstract][Full Text] [Related]
2. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
6. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Harding JJ
Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
[TBL] [Abstract][Full Text] [Related]
8. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
9. Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report.
Han JE; Cho HJ; Kim SS; Cheong JY
J Liver Cancer; 2021 Sep; 21(2):169-176. PubMed ID: 37383079
[TBL] [Abstract][Full Text] [Related]
10. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.
Roderburg C; Özdirik B; Wree A; Demir M; Tacke F
Hepat Oncol; 2020 May; 7(2):HEP20. PubMed ID: 32647565
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
13. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
Ozer M; George A; Goksu SY; George TJ; Sahin I
Front Oncol; 2021; 11():801379. PubMed ID: 34956912
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
15. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
16. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.
Lee SW; Yang SS; Lien HC; Peng YC; Tung CF; Lee TY
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013120
[TBL] [Abstract][Full Text] [Related]
17. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
18. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Leone P; Solimando AG; Fasano R; Argentiero A; Malerba E; Buonavoglia A; Lupo LG; De Re V; Silvestris N; Racanelli V
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065489
[TBL] [Abstract][Full Text] [Related]
19. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Yao X; Wang L; Gao J
Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
[TBL] [Abstract][Full Text] [Related]
20. Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
Nishida N; Kudo M
Dig Dis; 2017; 35(6):618-622. PubMed ID: 29040995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
